Svb Leerink Research Analysts Reduce Earnings Estimates for Blueprint Medicines Corp (NASDAQ:BPMC)

Share on StockTwits

Blueprint Medicines Corp (NASDAQ:BPMC) – Stock analysts at Svb Leerink decreased their FY2020 earnings estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Wednesday, August 14th. Svb Leerink analyst A. Berens now forecasts that the biotechnology company will post earnings of ($9.13) per share for the year, down from their prior estimate of ($8.92). Svb Leerink also issued estimates for Blueprint Medicines’ FY2021 earnings at ($5.87) EPS, FY2022 earnings at $0.51 EPS and FY2023 earnings at $7.13 EPS.

A number of other brokerages have also recently weighed in on BPMC. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Monday, June 17th. BidaskClub cut shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. Zacks Investment Research cut shares of Blueprint Medicines from a “buy” rating to a “sell” rating and set a $94.00 price target for the company. in a research report on Wednesday, August 7th. Raymond James reiterated a “market perform” rating on shares of Blueprint Medicines in a research report on Wednesday, August 14th. Finally, Deutsche Bank began coverage on shares of Blueprint Medicines in a research report on Thursday, July 18th. They set a “buy” rating and a $110.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $110.11.

Shares of BPMC opened at $78.57 on Monday. Blueprint Medicines has a 1-year low of $44.58 and a 1-year high of $102.98. The stock has a market cap of $4.13 billion, a PE ratio of -14.58 and a beta of 1.55. The firm has a 50-day simple moving average of $93.69 and a two-hundred day simple moving average of $84.43. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.52 and a quick ratio of 7.52.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($2.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.92) by ($0.12). Blueprint Medicines had a negative return on equity of 73.73% and a negative net margin of 4,268.74%. The firm had revenue of $5.11 million for the quarter, compared to analysts’ expectations of $1.39 million. During the same period last year, the firm earned ($0.62) earnings per share. Blueprint Medicines’s revenue for the quarter was down 87.7% on a year-over-year basis.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. grew its holdings in Blueprint Medicines by 4,594.1% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 798 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 781 shares in the last quarter. Whittier Trust Co. acquired a new position in Blueprint Medicines during the 2nd quarter worth approximately $97,000. Ladenburg Thalmann Financial Services Inc. grew its holdings in Blueprint Medicines by 62.8% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,097 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 423 shares in the last quarter. Trexquant Investment LP acquired a new position in Blueprint Medicines during the 2nd quarter worth approximately $203,000. Finally, Flinton Capital Management LLC acquired a new position in Blueprint Medicines during the 2nd quarter worth approximately $211,000. Institutional investors own 97.45% of the company’s stock.

In other Blueprint Medicines news, Director Nicholas Lydon sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $84.77, for a total transaction of $2,119,250.00. Following the completion of the transaction, the director now owns 166,527 shares in the company, valued at approximately $14,116,493.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $84.75, for a total transaction of $1,695,000.00. Following the transaction, the chief executive officer now owns 48,961 shares of the company’s stock, valued at approximately $4,149,444.75. The disclosure for this sale can be found here. Insiders sold 123,793 shares of company stock valued at $11,122,890 in the last 90 days. Company insiders own 4.02% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

See Also: What are popular green investing opportunities?

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AtriCure Inc.  Shares Purchased by First Light Asset Management LLC
AtriCure Inc. Shares Purchased by First Light Asset Management LLC
LaFleur & Godfrey LLC Has $10 Million Position in Woodward, Inc.Common Stock
LaFleur & Godfrey LLC Has $10 Million Position in Woodward, Inc.Common Stock
Novartis AG  Shares Purchased by LaFleur & Godfrey LLC
Novartis AG Shares Purchased by LaFleur & Godfrey LLC
AbbVie Inc  Shares Sold by LaFleur & Godfrey LLC
AbbVie Inc Shares Sold by LaFleur & Godfrey LLC
LaFleur & Godfrey LLC Cuts Stake in Procter & Gamble Co
LaFleur & Godfrey LLC Cuts Stake in Procter & Gamble Co
PETROLEO BRASIL/ADR  Holdings Increased by Lyxor Asset Management Inc.
PETROLEO BRASIL/ADR Holdings Increased by Lyxor Asset Management Inc.


© 2006-2019 Ticker Report